Dynavax Technologies Corporation

Dynavax Technologies — Conference Presentation (January 2025)

17 slides from Dynavax Technologies's conference presentation, Jan 13, 2025

  1. Slide 1: Corporate Presentation

    Corporate Presentation Using Proven, Innovative Adjuvant Technology to Help Protect the World Against Infectious Diseases January 2025 Nasdaq: DVAX

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about Dynavax's expected financial results and market

  3. Slide 3: Identify Strategic Opportunities to Accelerate Growth

    Identify Strategic Opportunities to Accelerate Growth • Continue disciplined allocation of capital aligned with corporate strategy to deliver long-term value through internal and external innovation • Prioritize external opportunities with high synergy assets in vaccines, or other modalities in infe

  4. Slide 4: Executing on Our Strategy: Preliminary FY 2024 Highlights

    Executing on Our Strategy: Preliminary FY 2024 Highlights1 © Copyright DYNAVAX 2025 4 | Achieved record annual HEPLISAV-B net product revenue in FY’24 HEPLISAV-B FY24 net product revenue: HEPLISAV-B total U.S. market share (as of Q3’ 24): $268M, up 26% YoY vs. $213M in FY23 ~44% in Q3 ’24 vs. ~41% i

  5. Slide 5: Commercial Product

    Commercial Product © Copyright DYNAVAX 2025 5 |

  6. Slide 6: HEPLISAV-B Clinical Outcomes

    0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 0 4 8 12 18 24 28 32 36 44 52 HEPLISAV-B Clinical Outcomes Higher and faster rates of protection HEPLISAV-B provided significantly higher rates of protection than Engerix-B at every time point in clinical trials HEPLISAV-B provided significantly higher rat

  7. Slide 7: Continued HEPLISAV-B Growth: Revenue & Market Share

    Continued HEPLISAV-B Growth: Revenue & Market Share 7 | Sequential Q3 HEPLISAV-B Vaccine Total U.S. Market Share1 32% 41% 44% 20% 30% 40% 50% Q3'22 Q3'23 Q3'24 Source: Internal data and company estimates. 1. Market share data are for Q3 of each year and do not reflect interim periods. 2. Dynavax fin

  8. Slide 8: HEPLISAV-B Market Opportunity Expected to Grow to Over $900M in U.S. by 2030

    HEPLISAV-B Market Opportunity Expected to Grow to Over $900 M in U.S. by 2030 © Copyright DYNAVAX 2025 8 | Market Opportunity ~8% CAGR Through 2030 Peak Market in 2030 Durable Long Term Market Opportunity Maintained Through 2040 2023 2030 2040 >$900M • HEPLISAV-B total market share expected to incre

  9. Slide 9: HEPLISAV-B Market Opportunity Expected to Grow to Over $900M in U.S. by 2030

    HEPLISAV-B Market Opportunity Expected to Grow to Over $900 M in U.S. by 2030 © Copyright DYNAVAX 2025 9 | HEPLISAV-B is the market share leader in projected largest growth segments (Retail and Prioritized IDNs) 2030 Projected Market Size: >$900 M2 Prioritized IDN/Clinics4 37% Small Clinics/ Ind. 25

  10. Slide 10: Vaccine Development: Herpes Zoster (Shingles) | Plague

    Vaccine Development Herpes Zoster (Shingles) | Plague © Copyright DYNAVAX 2025 10 |

  11. Slide 11: Shingles Program: New Options Needed

    Shingles Program: New Options Needed Current Market-Leading Vaccine Associated with Adverse Events1 Herpes Zoster (shingles) is an extremely painful consequence of the reactivation of a latent varicella-zoster virus (VZV), the same virus that causes varicella (chickenpox). 11 | 1. Package Insert - S

  12. Slide 12: Shingles Program: Phase 1/2 Trial Design

    Shingles Program: Phase 1/2 Trial Design Top-line results expected in Q3 2025 © Copyright DYNAVAX 2025 12 | Phase 1/2 randomized, active-controlled, dose escalation, multicenter trial of two-dose shingles vaccine Z-1018 conducted at Australian trial sites Evaluating the safety, tolerability, and imm

  13. Slide 13: Plague Vaccine Program

    13 | Program Status: Recent Updates: • Based on the results from a randomized, active- controlled Phase 2 clinical trial of the plague vaccine adjuvanted with CpG 1018, Dynavax and the DoD executed a new agreement for ~$30 million through the 1H 2027 to support additional Phase 2 clinical and manufa

  14. Slide 14: Financial Highlights

    Financial Highlights © Copyright DYNAVAX 2025 14 |

  15. Slide 15: Creating Value through Disciplined and Balanced Capital Allocation Strategy

    Creating Value through Disciplined and Balanced Capital Allocation Strategy 15 |© Copyright DYNAVAX 2025 $200M share repurchase program authorized in November 2024 Our capital allocation priorities include: 01 Maximizing HEPLISAV-B through targeted investments 02 Investing in pipeline leveraging CpG

  16. Slide 16: On Track to Achieve 2024 Financial Guidance Framework

    Expect positive net income for full year 2024 On Track to Achieve 2024 Financial Guidance Framework (1,2) 16 |© Copyright DYNAVAX 2025 HEPLISAV-B Performance Operating Expenses Driving Profitability Net Product Revenue $265-$270M Achieved $268M Gross Margin ~80% R&D Operating Expense $55-$65M SG&A O

  17. Slide 17: Identify Strategic Opportunities to Accelerate Growth

    Identify Strategic Opportunities to Accelerate Growth • Continue disciplined allocation of capital aligned with corporate strategy to deliver long-term value through internal and external innovation • Prioritize external opportunities with high synergy assets in vaccines, or other modalities in infe

Dynavax Technologies — Conference Presentation (January 2025) on 6ix